# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmacologic agonism recapitulate endogenous activation? The therapeutic window may be narrow.
**Confounds:**
- 5xFAD mice have aggressive amyloid deposition; microglial dynamics differ in human AD where plaques form over decades
- TREM2 agonism may enhance phagocytosis of *vulnerable synapses*, not just plaques (PMID 30742032 showed microglial engulfment of excitatory terminals)
- AL002c is hypothetical—has this been independently replicated?
**Counter-evidence:** TREM2 is a *risk factor* gene, not deterministic. Risk alleles explain ~3% of AD cases; the mechanistic chain from variant → pathology → therapeutic response assumes linearity that may not hold.
**Falsifying experiment:** Treat 12-month 5xFAD mice (established plaques) with AL002c. Hypothesis 1 predicts improved cognition and reduced plaque burden. **Alternative prediction:** No behavioral benefit despite increased microglial coverage (plaques persist).
**Revised confidence:** 0.65 (down from 0.78)
---
## Hypothesis 2: NLRP3 Inhibition
**Weakest link:** NLRP3 KO mice are developmental knockouts—compensatory pathways may explain protection, not direct inflammasome inhibition in adults.
**Confounds:**
- MCC950's BBB penetration in the cited paper (PMID 30638571) used 6-week chronic dosing in young mice; pharmacokinetics in symptomatic aged mice are unknown
- IL-1β infusion is acute; AD pathology develops over years—chronic IL-1β exposure may have different mechanisms
**Counter-evidence:** Phase II trials of NLRP3 inhibitors in inflammatory diseases (e.g., dapansutrile) showed limited efficacy—BBB penetration remains a significant barrier.
**Falsifying experiment:** Treat 12-month APP/PS1 mice with MCC950 after behavioral deficits are established. Hypothesis 2 predicts reversal of deficits. **Alternative prediction:** No behavioral rescue; detectable IL-1β in plasma but not CSF.
**Revised confidence:** 0.58 (down from 0.72)
---
## Hypothesis 3: TFEB
**Weakest link:** TFEB(S211A) is phosphorylation-deficient, but nuclear translocation also requires mTORC1-independent pathways (calcineurin, ERK). Overexpression may not functionally activate lysosomal biogenesis.
**Confounds:**
- AAV9 delivery efficiency in aged mice varies significantly; 10⁹ genomic copies may be insufficient for therapeutic effect
- M83 mice develop α-syn pathology but not human LB disease; pathology is primarily axonal, not cellular
- mTORC1 inhibition (rapamycin) has pleiotropic effects—attributing effects solely to TFEB ignores systemic autophagy dysregulation
**Falsifying experiment:** Measure autophagy flux ( tandem RFP-GFP-LC3) in vivo after AAV9-TFEB injection. Hypothesis 3 predicts increased autophagosome-lysosome fusion. **Alternative prediction:** LC3-II accumulates without degradation (blocked at lysosomal step).
**Revised confidence:** 0.55 (down from 0.70)
---
## Hypothesis 4: SIRT1 in C9orf72
**Weakest link:** SIRT1 has dozens of substrates—activation in vivo does not guarantee specific engagement with PINK1/Parkin mitophagy pathway.
**Confounds:**
- Drosophila models of C9orf72 are not validated for translational relevance to human disease
- SRT2104 is described but has poor oral bioavailability; pharmacokinetics in mice are poorly characterized
- C9orf72 KO mice show mitochondrial dysfunction *and* lysosomal accumulation—SIRT1 activation addresses only the mitochondrial component
**Counter-evidence:** C9orf72 haploinsufficiency vs. toxic gain-of-function is unresolved; SIRT1 may worsen or improve either mechanism unpredictably. Human trials of resveratrol showed no cognitive benefit in AD (PMID 24445164).
**Falsifying experiment:** Measure DPR levels (poly-GA, poly-GR) via ELISA in cortex after SRT2104 treatment. Hypothesis 4 predicts reduction. **Alternative prediction:** DPR accumulation continues; survival benefit is due to general neuroprotection, not C9orf72-specific pathway.
**Revised confidence:** 0.52 (down from 0.68)
---
## Hypothesis 5: CDK5 Inhibition
**Weakest link:** Dinaciclib is a pan-CDK inhibitor (CDK1/2/5/9)—using it as a "CDK5 inhibitor" is imprecise. The experiment conflates CDK family inhibition with specific CDK5 targeting.
**Confounds:**
- Optogenetic 40Hz stimulation is highly non-physiological; may induce seizure-like activity in aged mice
- AAV-dnCDK5 expression needs independent validation (antibody confirmation, enzymatic assay)
- Exosomal tau spread in human AD is correlative; causality not established
**Counter-evidence:** CDK5 is essential for memory consolidation—chronic inhibition may impair cognitive function. The hypothesized therapeutic window is narrow.
**Falsifying experiment:** Use a selective CDK5 peptide inhibitor (CIP) instead of dnCDK5. Compare exosomal tau from treated vs. control mice in a primary neuron uptake assay. **Alternative prediction:** dnCDK5 reduces p-tau but exosomal tau unchanged—tau propagation uses non-exosomal mechanisms.
**Revised confidence:** 0.60 (down from 0.74)
---
## Hypothesis 6: NRF2 Across Diseases
**Weakest link:** NRF2 is a general stress response pathway. "Neuroprotection" across ALS, AD, and PD is too broad—each disease has distinct etiologies that converge only at the terminal oxidative stress stage.
**Confounds:**
- CDDO-EA has off-target effects (PPARγ, NF-κB inhibition); attributing results solely to NRF2 is problematic
- NRF2 activation in post-mortem AD brains may be a *compensatory* response, not a driver of pathology—activating it pharmacologically may not add benefit
**Counter-evidence:** Clinical trials of NRF2 activators (sulforaphane, bardoxolone) in CKD and COPD showed mixed results; BBB penetration was insufficient in some studies.
**Falsifying experiment:** Include NRF2 KO mice in each model. Hypothesis 6 predicts CDDO-EA fails in NRF2 KO mice. **Alternative prediction:** NRF2 KO mice show same protection—CDDO-EA acts via NRF2-independent pathways.
**Revised confidence:** 0.60 (down from 0.76)
---
## Hypothesis 7: NMDAR Subtype Targeting
**Weakest link:** Synaptic vs. extrasynaptic NMDAR compartmentalization is technically difficult to confirm in vivo—regional specificity assumptions may not hold.
**Confounds:**
- Ifenprodil also binds sigma-1 receptors; neuroprotective effects may be sigma-1 mediated, not GluN2B-specific
- TCN-201 blocks synaptic GluN2A but has off-target effects at high doses
**Counter-evidence:** Memantine (current AD therapeutic) preferentially blocks extrasynaptic NMDAR—yet clinical benefit is modest. This suggests the synaptic/extrasynaptic dichotomy may be oversimplified in human disease.
**Falsifying experiment:** Use genetically modified mice with conditional GluN2B deletion in forebrain excitatory neurons (not global KO). **Alternative prediction:** Synapse loss continues despite extrasynaptic blockade—compensatory mechanisms bypass the hypothesized pathway.
**Revised confidence:** 0.48 (down from 0.65)
---
## Summary of Revised Confidence Scores
| Hypothesis | Original | Revised | Primary Issue |
|------------|----------|---------|--------------|
| TREM2 | 0.78 | 0.65 | R47H ≠ pharmacologic agonism; synapse engulfment risk |
| NLRP3 | 0.72 | 0.58 | Developmental compensation; BBB penetration uncertainty |
| TFEB | 0.70 | 0.55 | AAV delivery efficiency; non-physiological mechanism |
| SIRT1 | 0.68 | 0.52 | Pleiotropic targets; Drosophila model validity |
| CDK5 | 0.74 | 0.60 | Non-selective inhibitor; optogenetic confounds |
| NRF2 | 0.76 | 0.60 | Overly broad mechanism; terminal-stage intervention |
| NMDAR | 0.65 | 0.48 | Receptor compartmentalization unproven |
**Across all hypotheses:**
- Mouse model validity (aggressive transgene expression ≠ human disease)
- Therapeutic timing (pre-symptomatic vs. established pathology)
- Mechanistic specificity (pleiotropic pathways, off-target effects)
The highest-confidence targets remain H1 (TREM2) and H5 (CDK5), but both require significant experimental refinement before clinical translation is plausible.